# LyondellBasell Industries N.V. (LYB) â€“ Valuation Analysis (November 2025)

**Analysis Date:** November 3, 2025  
**Data Period:** Q3 2025 Results and Valuation Metrics  
**Current Stock Price:** $46.27 (as of November 3, 2025)  
**Analyst:** Investment Analysis Framework

---

## Executive Summary

**BLUF: LYB trades at deep cyclical trough valuation of 0.41x Price/Sales and 12.99x Forward P/E, significantly below historical averages. Base case valuation suggests 30-50% upside potential as markets recover, with bull case showing 50-100% upside potential. Current EV/EBITDA of 13.51x (12.9x excluding items) reflects cyclical pressure but reasonable for recovery scenario. Sum-of-parts analysis supports valuation recovery as capacity rationalization progresses and margins normalize. Key catalysts include accelerating capacity rationalization, margin expansion, and multiple expansion as cycle normalizes. Recommendation: Attractive valuation for patient value investors - current price reflects deep cyclical trough with significant recovery potential.**

LyondellBasell is trading at deep cyclical trough valuations, reflecting the prolonged industry downturn and near-term challenges. However, the company's strong structural advantages, accelerating capacity rationalization, and improving market dynamics suggest significant valuation recovery potential as markets normalize. Multiple valuation methodologies support upside potential from current levels.

---

## Current Valuation Metrics

### Market Valuation (November 3, 2025)
| Metric                         | Value      | Historical Range | Status         |
|--------------------------------|------------|------------------|----------------|
| **Stock Price**                | $46.27     | $30-$100+        | Trough         |
| **Market Cap**                 | $15.87B    | $24B-$31B        | Below Average  |
| **Enterprise Value**           | $27.40B    | $32B-$41B        | Below Average  |
| **Price/Sales**                | 0.41x      | 0.5-1.0x         | Deep Trough    |
| **Trailing P/E**               | 104.96x    | 10-20x           | Distorted*     |
| **Forward P/E**                | 12.99x     | 10-25x           | Reasonable     |
| **PEG Ratio (5yr)**           | 0.85       | 0.8-2.0x         | Attractive     |
| **Price/Book**                 | 1.33x      | 1.5-2.5x         | Below Average  |
| **EV/Revenue**                 | 0.71x      | 0.8-1.2x         | Below Average  |
| **EV/EBITDA (Reported)**      | 13.51x     | 7-12x            | Elevated       |
| **EV/EBITDA (Ex. Items)**     | 12.9x**    | 7-12x            | Elevated       |

*Trailing P/E distorted by asset write-downs in Q3 2025  
**Estimated based on TTM EBITDA excluding identified items of $2.126B

### Valuation Context
- **Current Valuation:** Trading at deep cyclical trough multiples
- **Historical Comparison:** Significantly below historical averages
- **Peak Valuation:** Historical peak multiples were 2-3x current levels
- **Recovery Potential:** Significant upside potential as markets recover

---

## Comparable Company Analysis

### Peer Group Selection
**Global Petrochemical Companies:**
- Dow Chemical (DOW)
- ExxonMobil Chemical (XOM)
- BASF (BASFY)
- SABIC (Private)
- Ineos (Private)

**Challenges with Comparables:**
- Limited pure-play public comparables
- Diverse business mixes affecting comparability
- Regional differences in cost structures
- Cyclical timing differences

### Valuation Comparison (Estimated)
| Company              | EV/EBITDA | P/E Ratio | Price/Sales | Notes                    |
|----------------------|----------|-----------|-------------|--------------------------|
| **LYB**              | 12.9x*    | 12.99x    | 0.41x       | Current (trough)         |
| **Dow Chemical**     | 8-12x     | 10-15x    | 0.6-0.8x    | Similar cyclical position|
| **BASF**             | 7-10x     | 8-12x     | 0.5-0.7x    | European exposure        |
| **Industry Average** | 8-12x     | 10-15x    | 0.5-0.8x    | Normalized multiples    |

*Excluding identified items

### Relative Valuation Assessment
- **LYB vs Peers:** Trading at similar or elevated multiples vs peers
- **Cyclical Position:** All peers facing cyclical challenges
- **Regional Differences:** LYB's cost advantages not fully reflected
- **Recovery Potential:** Similar recovery potential across peer group

---

## Discounted Cash Flow Analysis

### DCF Assumptions

**Revenue Projections:**
- **2025:** $38.7B (TTM run rate)
- **2026:** $40.0B (+3.4% recovery)
- **2027:** $42.0B (+5.0% recovery)
- **2028:** $44.0B (+4.8% normalized growth)
- **2029:** $46.0B (+4.5% normalized growth)
- **Terminal:** 3% terminal growth rate

**EBITDA Margin Assumptions:**
- **2025:** 5.5% (current TTM excluding items)
- **2026:** 7.0% (margin recovery)
- **2027:** 9.0% (further recovery)
- **2028:** 11.0% (normalized margins)
- **2029:** 12.0% (cycle peak margins)
- **Terminal:** 11.0% (normalized)

**EBITDA Projections:**
- **2025:** $2.1B (TTM excluding items)
- **2026:** $2.8B (+33% recovery)
- **2027:** $3.8B (+36% recovery)
- **2028:** $4.8B (+26% normalized)
- **2029:** $5.5B (+15% normalized)
- **Terminal:** Growing at 3%

**Capital Expenditures:**
- **2025:** $1.7B
- **2026:** $1.2B (reduced guidance)
- **2027-2029:** $1.5B (normalized)
- **Terminal:** $1.5B growing at 3%

**Discount Rate:**
- **WACC:** 9.0% (estimated)
- **Terminal Growth:** 3.0%
- **Tax Rate:** 25% (normalized)

### DCF Valuation Results

**Base Case DCF:**
- **Enterprise Value:** $32-35B
- **Equity Value:** $20-23B
- **Per Share Value:** $62-71
- **Upside Potential:** 34-53% from current $46.27

**Bull Case DCF (Faster Recovery):**
- **Enterprise Value:** $38-42B
- **Equity Value:** $26-30B
- **Per Share Value:** $81-93
- **Upside Potential:** 75-101% from current

**Bear Case DCF (Prolonged Downturn):**
- **Enterprise Value:** $25-28B
- **Equity Value:** $13-16B
- **Per Share Value:** $40-50
- **Downside Risk:** 14-32% from current

---

## Sum-of-Parts Valuation

### Segment Valuation

**Olefins & Polyolefins Americas:**
- **Revenue:** ~$15B (estimated)
- **EBITDA:** $428M (Q3 annualized, excluding items)
- **Multiple:** 8-10x EV/EBITDA (normalized)
- **Value:** $3.4-4.3B

**Olefins & Polyolefins EAI:**
- **Revenue:** ~$8B (estimated)
- **EBITDA:** $48M (Q3 annualized, excluding items)
- **Multiple:** 7-9x EV/EBITDA (normalized)
- **Value:** $0.3-0.4B

**Intermediates & Derivatives:**
- **Revenue:** ~$10B (estimated)
- **EBITDA:** $290M (Q3 annualized, excluding items)
- **Multiple:** 7-9x EV/EBITDA (normalized)
- **Value:** $2.0-2.6B

**Advanced Polymer Solutions:**
- **Revenue:** ~$4B (estimated)
- **EBITDA:** $47M (Q3 annualized, excluding items)
- **Multiple:** 6-8x EV/EBITDA (normalized)
- **Value:** $0.3-0.4B

**Technology:**
- **Revenue:** ~$1B (estimated)
- **EBITDA:** $34M (Q3 annualized, excluding items)
- **Multiple:** 10-12x EV/EBITDA (normalized)
- **Value:** $0.3-0.4B

**Sum-of-Parts Total:**
- **Operating Value:** $6.3-8.1B
- **Plus: Cash & Investments:** $1.8B
- **Less: Debt:** $12.9B
- **Net Equity Value:** ($4.8)-($2.2)B

**Note:** Sum-of-parts analysis challenging during cyclical downturn due to depressed segment earnings

---

## Asset-Based Valuation

### Net Asset Value
| Asset Category          | Value Estimate | Notes                        |
|------------------------|----------------|------------------------------|
| **Cash & Equivalents** | $1.8B          | Current balance              |
| **Net PPE**            | $16.5B         | Book value                   |
| **Goodwill & Intangibles** | $2.1B      | Book value (post impairments)|
| **Investments**         | $4.1B          | Book value                   |
| **Less: Total Debt**   | ($12.9B)       | Total debt                   |
| **Net Asset Value**    | $11.6B         | Book value basis             |
| **Per Share**          | $36            | Based on 322M shares          |

**Asset Value Considerations:**
- Book values may not reflect fair market values
- Cyclical downturn impacting asset values
- Strategic value of cost-advantaged assets
- Replacement cost considerations

---

## Scenario Analysis

### Base Case Scenario
**Assumptions:**
- Gradual recovery over 2026-2028
- Margin expansion to normalized levels
- Multiple expansion to historical averages
- Capacity rationalization improving balances

**Valuation:**
- **Target Price:** $60-70 per share
- **Upside Potential:** 30-51% from current $46.27
- **Time Horizon:** 2-4 years
- **Probability:** 60%

### Bull Case Scenario
**Assumptions:**
- Faster recovery driven by capacity rationalization
- Significant margin expansion
- Strong multiple expansion
- Accelerated demand recovery

**Valuation:**
- **Target Price:** $75-90 per share
- **Upside Potential:** 62-94% from current
- **Time Horizon:** 1-3 years
- **Probability:** 25%

### Bear Case Scenario
**Assumptions:**
- Prolonged downturn continuing
- Limited margin recovery
- Continued multiple compression
- Slower demand recovery

**Valuation:**
- **Target Price:** $35-45 per share
- **Downside Risk:** 3-24% from current
- **Time Horizon:** 2-4 years
- **Probability:** 15%

---

## Valuation Catalysts

### Upside Catalysts
1. **Capacity Rationalization:** Accelerating closures improving market balances
2. **Demand Recovery:** Gradual demand recovery as economic conditions improve
3. **Margin Expansion:** Pricing recovery driving margin expansion
4. **Multiple Expansion:** Valuation multiple expansion as cycle normalizes
5. **Portfolio Repositioning:** Completed repositioning improving returns

### Downside Risks
1. **Prolonged Downturn:** Industry downturn lasting longer than expected
2. **Competitive Pressure:** Continued competitive pressure from oversupply
3. **Economic Weakness:** Economic weakness impacting demand recovery
4. **Margin Compression:** Continued margin compression if recovery delayed
5. **Multiple Compression:** Further multiple compression if recovery delayed

---

## Price Target and Recommendation

### Price Target: $60-70 per Share (Base Case)

**Rationale:**
- DCF analysis supports $62-71 per share valuation
- Historical valuation multiples suggest recovery potential
- Base case scenario assuming gradual recovery
- 30-51% upside potential from current levels

### Investment Recommendation: Buy

**Target Audience:**
- Patient value investors
- Cyclical recovery investors
- Long-term oriented investors

**Investment Rationale:**
- Deep cyclical trough valuation
- Strong structural advantages
- Accelerating capacity rationalization
- Strong financial position
- Significant recovery potential

**Investment Horizon:**
- **Short-term:** 1-2 years - Navigating cyclical challenges
- **Medium-term:** 2-4 years - Recovery and value creation
- **Long-term:** 4+ years - Structural growth

**Key Considerations:**
- Requires tolerance for near-term volatility
- Cyclical recovery timing uncertain
- Strong balance sheet providing downside protection
- Structural advantages supporting long-term value creation

---

## Valuation Summary

LyondellBasell is trading at deep cyclical trough valuations, reflecting the prolonged industry downturn. However, multiple valuation methodologies suggest significant upside potential as markets recover. The combination of improving market dynamics, strong structural advantages, and accelerating capacity rationalization supports a base case valuation of $60-70 per share, representing 30-51% upside potential from current levels.

**Key Valuation Points:**
1. Deep cyclical trough valuation with recovery potential
2. DCF analysis supports $62-71 per share base case
3. Historical multiples suggest significant recovery potential
4. Strong structural advantages supporting valuation recovery
5. Accelerating capacity rationalization improving outlook

**Valuation Case:** Attractive valuation for patient value investors with significant recovery potential as markets normalize.

---

## Related Documents
- [Financial Analysis](2025_11_03_financial_analysis.md)
- [Market Analysis](2025_11_03_market_analysis.md)
- [Investment Thesis](2025_11_03_investment_thesis.md)
- [Risk Assessment](2025_11_03_risk_assessment.md)

*Analysis completed November 3, 2025. Valuation based on comprehensive financial analysis and market dynamics.*
